ACRS Q3 2022 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q3 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$19M+1046.4% YoY

Gross Profit

$11M56.8% margin

Operating Income

-$21M-109.8% margin

Net Income

-$20M-104.9% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+1144.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$268M

Total Liabilities

$48M

Stockholders' Equity

$220M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$2M	+1046.4%
Gross Profit	$11M	$560,000	+1827.7%
Operating Income	-$21M	-$20M	-2.9%
Net Income	-$20M	-$21M	+5.6%

Revenue Segments

License and Service

$18M94%

Contract research

$1M6%

Other

$30,0000%